Ilaria Motta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3967712/publications.pdf

Version: 2024-02-01

933447 839539 26 335 10 18 h-index citations g-index papers 28 28 28 649 times ranked citing authors all docs docs citations

#	Article	IF	CITATIONS
1	Tenofovir Plasma Concentrations According to Companion Drugs: a Cross-Sectional Study of HIV-Positive Patients with Normal Renal Function. Antimicrobial Agents and Chemotherapy, 2013, 57, 1840-1843.	3.2	41
2	Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. BMC Infectious Diseases, 2013, 13, 563.	2.9	39
3	Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 59-82.	3.3	36
4	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 241-245.	3.0	27
5	A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. Journal of Antimicrobial Chemotherapy, 2015, 70, 2572-2575.	3.0	23
6	Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. AIDS Research and Human Retroviruses, 2016, 32, 409-411.	1.1	19
7	HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients. AIDS Research and Human Retroviruses, 2015, 31, 999-1008.	1.1	18
8	Cerebrospinal Fluid Viral Load and Neopterin in HIV-Positive Patients with Undetectable Viraemia. Antiviral Therapy, 2017, 22, 539-543.	1.0	17
9	Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a crossâ€sectional study in rural <scp>B</scp> urundi. British Journal of Clinical Pharmacology, 2015, 79, 801-808.	2.4	15
10	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. Pharmacogenomics, 2017, 18, 865-880.	1.3	13
11	The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study. Clinical Pharmacology and Therapeutics, 2019, 106, 450-457.	4.7	13
12	Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
13	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 307-308.	3.0	10
14	Risk factors for mortality in patients with (i) Staphylococcus aureus (i) bloodstream infection. Journal of Chemotherapy, 2016, 28, 187-190.	1.5	10
15	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. International Journal of Pharmaceutics, 2016, 497, 287-292.	5.2	10
16	Tuberculosis transmission among children and adolescents in schools and other congregate settings: a systematic review. New Microbiologica, 2019, 41, 282-290.	0.1	7
17	Pharmacokinetics of firstâ€line antitubercular drugs in plasma and PBMCs. British Journal of Clinical Pharmacology, 2017, 83, 1146-1148.	2.4	5
18	Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. International Journal of Antimicrobial Agents, 2021, 57, 106297.	2.5	4

#	Article	IF	CITATIONS
19	Molecular epidemiology of methicillin-resistant S. aureus in the ICU setting. Intensive Care Medicine, 2014, 40, 759-760.	8.2	3
20	Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. Journal of Antimicrobial Chemotherapy, 2018, 73, 546-548.	3.0	3
21	Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. Antiviral Therapy, 2021, 25, 327-333.	1.0	3
22	Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. Infezioni in Medicina, 2014, 22, 107-11.	1.1	3
23	A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. Infezioni in Medicina, 2015, 23, 367-9.	1.1	3
24	Ulcerative pyoderma gangrenosum in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2019, 4, 488.	8.1	1
25	Wound botulism after traumatic open fracture in Italy. Infezioni in Medicina, 2015, 23, 280-2.	1.1	1
26	The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study. Antimicrobial Agents and Chemotherapy, 2022, , e0013622.	3.2	0